Vanda Pharmaceuticals
VNDA
182 hedge funds and large institutions have $947M invested in Vanda Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 60 increasing their positions, 75 reducing their positions, and 15 closing their positions.
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
1% more funds holding
Funds holding: 181 → 182 (+1)
0.51% more ownership
Funds ownership: 98.78% → 99.29% (+0.51%)
20% less call options, than puts
Call options by funds: $2.07M | Put options by funds: $2.57M
20% less capital invested
Capital invested by funds: $1.18B → $947M (-$232M)
20% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 75
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.3M |
| 2 |
Millennium Management
New York
|
+$6.15M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.23M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$4.89M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.1M |
| 2 |
Morgan Stanley
New York
|
-$3.74M |
| 3 |
PIM
Profit Investment Management
North Bethesda,
Maryland
|
-$3.12M |
| 4 |
BlackRock
New York
|
-$2.88M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.35M |
VNDA Hedge Fund Activity: Q3 2021 in Review
182 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2021, worth a combined $947M — down 20% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VNDA positions and 15 closed out — a net gain of 4 holders — while 60 added to existing stakes and 75 trimmed.
The largest buyer was Nuveen, adding an estimated $10.3M. The largest seller was Armistice Capital, cutting an estimated $13.1M.
- 182 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2021, up from 181 in Q2 2021.
- Funds reported $947M of Vanda Pharmaceuticals stock for Q3 2021, down 20% quarter-over-quarter.
- 19 funds opened new Vanda Pharmaceuticals positions in Q3 2021 and 15 closed out, a net change of +4 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2021 was Nuveen, an estimated $10.3M added.
- The largest Vanda Pharmaceuticals seller in Q3 2021 was Armistice Capital, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2021.